Jeevan Shetty
Celgene Corporation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jeevan Shetty as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:04 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03342404 · A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-ThalassemiaCelgene · completed · Thalassemia · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:04 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- 312 citationsRCR 13.3
- A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.N Engl J Med · 2020253 citationsRCR 12.3
- 158 citationsRCR 15.1
- 90 citationsRCR 2.5
- Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.N Engl J Med · 202689 citationsRCR 44.5
- Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.Lancet Haematol · 202259 citationsRCR 4.3
- The effect of three mouthwashes on radiation-induced oral mucositis in patients with head and neck malignancies: a randomized control trial.J Cancer Res Ther · 200843 citationsRCR 1.6
- Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.J Clin Oncol · 202232 citationsRCR 2.2
- Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.Clin Cancer Res · 202329 citationsRCR 2.1
- Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema.Indian J Ophthalmol · 201810 citationsRCR 0.6